MedTrace Logo

Neoadjuvant Endocrine Therapy in Breast Cancer

NCT03397537 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2018-01-17

No results posted yet for this study

Summary

The study aimed to compare the duration to complete or partial response (CR/PR) and the overall response rates (ORR) after six months of neoadjuvant endocrine therapy between pre-menopausal group and post-menopausal group with highly endocrine responsive operable mammary carcinoma.

Conditions

  • Highly Endocrine Responsive Operable Breast Cancer

Interventions

DRUG

Letrozole 2.5Mg Tablet

letrozole 2.5mg p.o.qd

DRUG

GnRH analogue

3.75 mg triptorelin im. q28d

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03397537 on ClinicalTrials.gov